Re: Dr Shoe and CSM (Cholestyramine therapy paper in Neurotoxicology and Teratology - Sept 2006)

[Guest guest]

I think the variation in mycotoxin metabolism is significant, but mold

is still dangerous to people who are not in that 24%

Witness the situation in St 's Parish - the suburb of New Orleans

that was devastated by Hurricane Katrina. There, the number of people

affected was well over 24%. And when cholestyramine is used in animal

husbandry to allow farmers to feed cheaper, slightly contaminated feed

to animals, it helps all of the animals. There are differences in the

amount it helps, but those differences are maybe a ratio of several to

one in tolerance.. If the level of a poison is VERY high, even the

most resilient creatures still will get sick.

Here is the PubMed ref for one of Dr. Shoemaker's papers on

cholestyramine therapy for SBS.

Neurotoxicol Teratol. 2006 Sep-Oct;28(5):573-88. Epub 2006 Aug 7.

Sick building syndrome (SBS) and exposure to water-damaged

buildings: time series study, clinical trial and mechanisms.

Shoemaker RC, House DE.

Chronic Fatigue Center, 500 Market Street, Suite 103, Pocomoke

City, MD 21851, USA. ritchieshoemaker@...

<ritchieshoemaker@...>

Occupants of water-damaged buildings (WDBs) with evidence of

microbial amplification often describe a syndrome involving multiple

organ systems, commonly referred to as " sick building syndrome " (SBS),

following chronic exposure to the indoor air. Studies have

demonstrated that the indoor air of WDBs often contains a complex

mixture of fungi, mycotoxins, bacteria, endotoxins, antigens,

lipopolysaccharides, and biologically produced volatile compounds. A

case-series study with medical assessments at five time points was

conducted to characterize the syndrome after a double-blinded,

placebo-controlled clinical trial conducted among a group of study

participants investigated the efficacy of cholestyramine (CSM)

therapy. The general hypothesis of the time series study was that

chronic exposure to the indoor air of WDBs is associated with SBS.

Consecutive clinical patients were screened for diagnosis of SBS using

criteria of exposure potential, symptoms involving at least five organ

systems, and the absence of confounding factors. Twenty-eight cases

signed voluntary consent forms for participation in the time-series

study and provided samples of microbial contaminants from

water-damaged areas in the buildings they occupied. Twenty-six

participants with a group-mean duration of illness of 11 months

completed examinations at all five study time points. Thirteen of

those participants also agreed to complete a double-blinded,

placebo-controlled clinical trial. Data from Time Point 1 indicated a

group-mean of 23 out of 37 symptoms evaluated; and visual contrast

sensitivity (VCS), an indicator of neurological function, was

abnormally low in all participants. Measurements of matrix

metalloproteinase 9 (MMP9), leptin, alpha melanocyte stimulating

hormone (MSH), vascular endothelial growth factor (VEGF),

immunoglobulin E (IgE), and pulmonary function were abnormal in 22,

13, 25, 14, 1, and 7 participants, respectively. Following 2 weeks of

CSM therapy to enhance toxin elimination rates, measurements at Time

Point 2 indicated group-means of 4 symptoms with 65% improvement in

VCS at mid-spatial frequency-both statistically significant

improvements relative to Time Point 1. Moderate improvements were seen

in MMP9, leptin, and VEGF serum levels. The improvements in health

status were maintained at Time Point 3 following a 2-week period

during which CSM therapy was suspended and the participants avoid

re-exposure to the WDBs. Participants reoccupied the respective WDBs

for 3 days without CSM therapy, and all participants reported relapse

at Time Point 4. The group-mean number of symptoms increased from 4 at

Time Point 2 to 15 and VCS at mid-spatial frequency declined by 42%,

both statistically significant differences relative to Time Point 2.

Statistically significant differences in the group-mean levels of MMP9

and leptin relative to Time Point 2 were also observed. CSM therapy

was reinstated for 2 weeks prior to assessments at Time Point 5.

Measurements at Time Point 5 indicated group-means of 3 symptoms and a

69% increase in VCS, both results statistically different from those

at Time Points 1 and 4. Optically corrected Snellen Distance

Equivalent visual acuity scores did not vary significantly over the

course of the study. Group-mean levels of MMP9 and leptin showed

statistically significant improvement at Time Point 5 relative to Time

Points 1 and 4, and the proportion of participants with abnormal VEGF

levels was significantly lower at Time Point 5 than at Time Point 1.

The number of participants at Time Point 5 with abnormal levels of

MMP9, leptin, VEGF, and pulmonary function were 10, 10, 9, and 7,

respectively. The level of IgE was not re-measured because of the low

incidence of abnormality at Time Point 1, and MSH was not re-measured

because previously published data indicated a long time course for MSH

improvement. The results from the time series study supported the

general study hypothesis that exposure to the indoor air of WDBs is

associated with SBS. High levels of MMP9 indicated that exposure to

the complex mixture of substances in the indoor air of the WDBs

triggered a pro-inflammatory cytokine response. A model describing

modes of action along a pathway leading to biotoxin-associated illness

is presented to organize current knowledge into testable hypotheses.

The model links an inflammatory response with tissue hypoxia, as

indicated by abnormal levels of VEGF, and disruption of the

proopiomelanocortin pathway in the hypothalamus, as evidenced by

abnormalities in leptin and MSH levels. Results from the clinical

trial on CSM efficacy indicated highly significant improvement in

group-mean number of symptoms and VCS scores relative to baseline in

the 7 participants randomly assigned to receive 2 weeks of CSM

therapy, but no improvement in the 6 participants assigned placebo

therapy during that time interval. However, those 6 participants also

showed a highly significant improvement in group-mean number of

symptoms and VCS scores relative to baseline following a subsequent

2-week period of CSM therapy. Because the only known benefit of CSM

therapy is to enhance the elimination rates of substances that

accumulate in bile by preventing re-absorption during enterohepatic

re-circulation, results from the clinical trial also supported the

general study hypothesis that SBS is associated with exposure to WDBs

because the only relevant function of CSM is to bind and remove

toxigenic compounds. Only research that focuses on the signs,

symptoms, and biochemical markers of patients with persistent illness

following acute and/or chronic exposure to WDBs can further the

development of the model describing modes of action in the

biotoxin-associated pathway and guide the development of innovative

and efficacious therapeutic interventions.

Publication Types:

* Clinical Trial

* Comparative Study

* Randomized Controlled Trial

PMID: 17010568 [PubMed - indexed for MEDLINE]

On Fri, Sep 26, 2008 at 2:07 PM, <kdeanstudios@...> wrote:

>

> CRIS< SEEING YOU MUST BE A Dr-will you explain why CSM is PIssing in the

> wind?-and making things worse. NO one says there is one therapy that

> works for everyone. A carefull reading of Mold Warriors shows-that

> although Dr Shoe perscribes CSM for all who have biotoxins-they are only

> necessary for those who can not bind out the toxins by themselves or

> with other therapies. To clarify further-it is the only toxin-binder

> that Dr Shoe uses ,because it has been proven to work. If you still

> remain sick with the use of this front line therapy-he has numerouse

> tests and therapies to help you heal. I myself got better from a

> horrible exposure in 1991 with massive vit c-therapy-recommended by a

> Dr. Since then massive vit C has been proven to bind many toxins out of

> the body-but with a price-kindey stones-which I had sporadically for 2

> years after.-but all the mold symptoms went away with this therapy-now I

> prefer CSM

> Thanks,

>

> _